These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 18063195)

  • 1. Erlotinib administration for advanced non-small cell lung cancer during the first 2 months of unrecognized pregnancy.
    Zambelli A; Prada GA; Fregoni V; Ponchio L; Sagrada P; Pavesi L
    Lung Cancer; 2008 Jun; 60(3):455-7. PubMed ID: 18063195
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Docetaxel, gemcitabine, and cisplatin administered for non-small cell lung cancer during the first and second trimester of an unrecognized pregnancy.
    Kim JH; Kim HS; Sung CW; Kim KJ; Kim CH; Lee KY
    Lung Cancer; 2008 Feb; 59(2):270-3. PubMed ID: 17688967
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chemotherapy for a patient with advanced non-small-cell lung cancer during pregnancy: a case report and a review of chemotherapy treatment during pregnancy.
    Jänne PA; Rodriguez-Thompson D; Metcalf DR; Swanson SJ; Greisman HA; Wilkins-Haug L; Johnson BE
    Oncology; 2001; 61(3):175-83. PubMed ID: 11574771
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized phase II trial of erlotinib or standard chemotherapy in patients with advanced non-small-cell lung cancer and a performance status of 2.
    Lilenbaum R; Axelrod R; Thomas S; Dowlati A; Seigel L; Albert D; Witt K; Botkin D
    J Clin Oncol; 2008 Feb; 26(6):863-9. PubMed ID: 18281658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incorporating bevacizumab and erlotinib in the combined-modality treatment of stage III non-small-cell lung cancer: results of a phase I/II trial.
    Socinski MA; Stinchcombe TE; Moore DT; Gettinger SN; Decker RH; Petty WJ; Blackstock AW; Schwartz G; Lankford S; Khandani A; Morris DE
    J Clin Oncol; 2012 Nov; 30(32):3953-9. PubMed ID: 23045594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of erlotinib throughout pregnancy: a case-report of a patient with metastatic lung adenocarcinoma.
    Rivas G; Llinás N; Bonilla C; Rubiano J; Cuello J; Arango N
    Lung Cancer; 2012 Aug; 77(2):469-72. PubMed ID: 22534670
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lung cancer and pregnancy.
    Sarıman N; Levent E; Yener NA; Orki A; Saygı A
    Lung Cancer; 2013 Mar; 79(3):321-3. PubMed ID: 23254266
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Erlotinib in previously treated non-small-cell lung cancer.
    Shepherd FA; Rodrigues Pereira J; Ciuleanu T; Tan EH; Hirsh V; Thongprasert S; Campos D; Maoleekoonpiroj S; Smylie M; Martins R; van Kooten M; Dediu M; Findlay B; Tu D; Johnston D; Bezjak A; Clark G; Santabárbara P; Seymour L;
    N Engl J Med; 2005 Jul; 353(2):123-32. PubMed ID: 16014882
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancer.
    Reckamp KL; Krysan K; Morrow JD; Milne GL; Newman RA; Tucker C; Elashoff RM; Dubinett SM; Figlin RA
    Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3381-8. PubMed ID: 16740761
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized, double-blind, placebo-controlled, phase II trial of sorafenib and erlotinib or erlotinib alone in previously treated advanced non-small-cell lung cancer.
    Spigel DR; Burris HA; Greco FA; Shipley DL; Friedman EK; Waterhouse DM; Whorf RC; Mitchell RB; Daniel DB; Zangmeister J; Bass JD; Hainsworth JD
    J Clin Oncol; 2011 Jun; 29(18):2582-9. PubMed ID: 21576636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Upfront gefitinib/erlotinib treatment followed by concomitant radiotherapy for advanced lung cancer: a mono-institutional experience.
    Chang CC; Chi KH; Kao SJ; Hsu PS; Tsang YW; Chang HJ; Yeh YW; Hsieh YS; Jiang JS
    Lung Cancer; 2011 Aug; 73(2):189-94. PubMed ID: 21247653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of erlotinib in patients with advanced non-small-cell lung cancer (NSCLC): analysis of the Australian subpopulation of the TRUST study.
    Boyer M; Horwood K; Pavlakis N; De Souza P; Millward M; Stein B; Johnston M; Abell F; Rischin D
    Asia Pac J Clin Oncol; 2012 Sep; 8(3):248-54. PubMed ID: 22898114
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer.
    Herbst RS; Prager D; Hermann R; Fehrenbacher L; Johnson BE; Sandler A; Kris MG; Tran HT; Klein P; Li X; Ramies D; Johnson DH; Miller VA;
    J Clin Oncol; 2005 Sep; 23(25):5892-9. PubMed ID: 16043829
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase II study of enzastaurin in combination with erlotinib in patients with previously treated advanced non-small cell lung cancer.
    Clément-Duchêne C; Natale RB; Jahan T; Krupitskaya Y; Osarogiagbon R; Sanborn RE; Bernstein ED; Dudek AZ; Latz JE; Shi P; Wakelee HA
    Lung Cancer; 2012 Oct; 78(1):57-62. PubMed ID: 22809813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biomarker-based phase I dose-escalation, pharmacokinetic, and pharmacodynamic study of oral apricoxib in combination with erlotinib in advanced nonsmall cell lung cancer.
    Reckamp K; Gitlitz B; Chen LC; Patel R; Milne G; Syto M; Jezior D; Zaknoen S
    Cancer; 2011 Feb; 117(4):809-18. PubMed ID: 20922800
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prolonged control of bone metastases in non-small-cell lung cancer patients treated with gefitinib.
    Zampa G; Moscato M; Brannigan BW; Morabito A; Bell DW; Normanno N
    Lung Cancer; 2008 Jun; 60(3):452-4. PubMed ID: 18079016
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Erlotinib: small-molecule targeted therapy in the treatment of non-small-cell lung cancer.
    Smith J
    Clin Ther; 2005 Oct; 27(10):1513-34. PubMed ID: 16330289
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen.
    Johnson JR; Cohen M; Sridhara R; Chen YF; Williams GM; Duan J; Gobburu J; Booth B; Benson K; Leighton J; Hsieh LS; Chidambaram N; Zimmerman P; Pazdur R
    Clin Cancer Res; 2005 Sep; 11(18):6414-21. PubMed ID: 16166415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Final survival and safety results from a multicenter, open-label, phase 3b trial of erlotinib in patients with advanced nonsmall cell lung cancer.
    Spigel DR; Lin M; O'Neill V; Hainsworth JD
    Cancer; 2008 Jun; 112(12):2749-55. PubMed ID: 18438878
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Erlotinib after gefitinib failure in relapsed non-small cell lung cancer: clinical benefit with optimal patient selection.
    Hata A; Katakami N; Yoshioka H; Fujita S; Kunimasa K; Nanjo S; Otsuka K; Kaji R; Tomii K; Iwasaku M; Nishiyama A; Hayashi H; Morita S; Ishida T
    Lung Cancer; 2011 Nov; 74(2):268-73. PubMed ID: 21529987
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.